Srb Corp Nektar Therapeutics Transaction History

Srb Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $251,350 - $539,117	-14,864 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $96,286 - $112,747	-3,106 Reduced 17.28%	14,864 $529,000
Q1 2019 May 14, 2019	BUY	$31.58 - $46.35 $77,149 - $113,233	2,443 Added 15.73%	17,970 $604,000
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $219,948 - $409,466	7,228 Added 87.09%	15,527 $511,000
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $385,571 - $568,398	8,299 New	8,299 $505,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Srb Corp, based on Form 13F filings with the SEC.

Stay updated on Srb Corp with notifications on news.